Corcept Therapeutics | CORT - Operating Expenses


Corcept Therapeutics reported $214.5M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Ardelyx USD 120.12M 14.46M Dec/2025
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.8B 23M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026